187 related articles for article (PubMed ID: 12773039)
1. Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy.
Clement OO; Freeman CM; Hartmann RW; Handratta VD; Vasaitis TS; Brodie AM; Njar VC
J Med Chem; 2003 Jun; 46(12):2345-51. PubMed ID: 12773039
[TBL] [Abstract][Full Text] [Related]
2. Computational prediction of new CYP17 inhibitors based on pharmacophore modeling, virtual screening and docking approach.
Haidar S; Hartmann RW
Pharmazie; 2017 Sep; 72(9):529-536. PubMed ID: 29441980
[TBL] [Abstract][Full Text] [Related]
3. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer.
Hou Q; He C; Lao K; Luo G; You Q; Xiang H
Steroids; 2019 Oct; 150():108384. PubMed ID: 30885648
[TBL] [Abstract][Full Text] [Related]
5. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.
Rafferty SW; Eisner JR; Moore WR; Schotzinger RJ; Hoekstra WJ
Bioorg Med Chem Lett; 2014 Jun; 24(11):2444-7. PubMed ID: 24775307
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.
Pinto-Bazurco Mendieta MA; Negri M; Jagusch C; Müller-Vieira U; Lauterbach T; Hartmann RW
J Med Chem; 2008 Aug; 51(16):5009-18. PubMed ID: 18672868
[TBL] [Abstract][Full Text] [Related]
7. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.
Njar VC; Kato K; Nnane IP; Grigoryev DN; Long BJ; Brodie AM
J Med Chem; 1998 Mar; 41(6):902-12. PubMed ID: 9526564
[TBL] [Abstract][Full Text] [Related]
8. Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls.
Hille UE; Hu Q; Vock C; Negri M; Bartels M; Müller-Vieira U; Lauterbach T; Hartmann RW
Eur J Med Chem; 2009 Jul; 44(7):2765-75. PubMed ID: 19211174
[TBL] [Abstract][Full Text] [Related]
9. CYP17 inhibitors for prostate cancer treatment--an update.
Moreira VM; Salvador JA; Vasaitis TS; Njar VC
Curr Med Chem; 2008; 15(9):868-99. PubMed ID: 18473796
[TBL] [Abstract][Full Text] [Related]
10. Investigations on inhibitors of human 17 alpha-hydroxylase-17,20-lyase and their interactions with the enzyme. Molecular modelling of 17 alpha-hydroxylase-17,20-lyase, Part II.
Schappach A; Höltje HD
Pharmazie; 2001 Nov; 56(11):835-42. PubMed ID: 11817165
[TBL] [Abstract][Full Text] [Related]
11. Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.
Gianti E; Zauhar RJ
J Chem Inf Model; 2012 Oct; 52(10):2670-83. PubMed ID: 22924551
[TBL] [Abstract][Full Text] [Related]
12. Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases.
Salvador JA; Pinto RM; Silvestre SM
J Steroid Biochem Mol Biol; 2013 Sep; 137():199-222. PubMed ID: 23688836
[TBL] [Abstract][Full Text] [Related]
13. Novel mutation of the CYP17 gene in two unrelated patients with combined 17alpha-hydroxylase/17,20-lyase deficiency: demonstration of absent enzyme activity by expressing the mutant CYP17 gene and by three-dimensional modeling.
Patocs A; Liko I; Varga I; Gergics P; Boros A; Futo L; Kun I; Bertalan R; Toth S; Pazmany T; Toth M; Szücs N; Horanyi J; Glaz E; Racz K
J Steroid Biochem Mol Biol; 2005 Nov; 97(3):257-65. PubMed ID: 16176874
[TBL] [Abstract][Full Text] [Related]
14. The use of the novel substrate-heme complex approach in the derivation of a representation of the active site of the enzyme complex 17alpha-hydroxylase and 17,20-lyase.
Ahmed S
Biochem Biophys Res Commun; 2004 Apr; 316(3):595-8. PubMed ID: 15033441
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of 17alpha-hydroxylase/17,20-lyase (CYP17): potential agents for the treatment of prostate cancer.
Njar VC; Brodie AM
Curr Pharm Des; 1999 Mar; 5(3):163-80. PubMed ID: 10066888
[TBL] [Abstract][Full Text] [Related]
16. A-ring modified steroidal azoles retaining similar potent and slowly reversible CYP17A1 inhibition as abiraterone.
Garrido M; Peng HM; Yoshimoto FK; Upadhyay SK; Bratoeff E; Auchus RJ
J Steroid Biochem Mol Biol; 2014 Sep; 143():1-10. PubMed ID: 24508512
[TBL] [Abstract][Full Text] [Related]
17. [Three dimensional quantitative structure activity relationship of P450(17) alpha inhibitors of 17-substituted steroids].
Miao J; Ling YZ; Zhu N; Lei XP
Yao Xue Xue Bao; 2001 Jul; 36(7):507-10. PubMed ID: 12585081
[TBL] [Abstract][Full Text] [Related]
18. New CYP17 hydroxylase inhibitors: synthesis, biological evaluation, QSAR, and molecular docking study of new pregnenolone analogs.
Al-Masoudi NA; Ali DS; Saeed B; Hartmann RW; Engel M; Rashid S; Saeed A
Arch Pharm (Weinheim); 2014 Dec; 347(12):896-907. PubMed ID: 25251696
[TBL] [Abstract][Full Text] [Related]
19. Pharmacophore filtering and 3D-QSAR in the discovery of new JAK2 inhibitors.
Dhanachandra Singh Kh; Karthikeyan M; Kirubakaran P; Nagamani S
J Mol Graph Model; 2011 Sep; 30():186-97. PubMed ID: 21831680
[TBL] [Abstract][Full Text] [Related]
20. CYP17 inhibitors. Annulations of additional rings in methylene imidazole substituted biphenyls: synthesis, biological evaluation and molecular modelling.
Pinto-Bazurco Mendieta MA; Negri M; Hu Q; Hille UE; Jagusch C; Jahn-Hoffmann K; Müller-Vieira U; Schmidt D; Lauterbach T; Hartmann RW
Arch Pharm (Weinheim); 2008 Oct; 341(10):597-609. PubMed ID: 18720339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
